Clinical Trial Detail

NCT ID NCT02563002
Title Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Merck Sharp & Dohme Corp.
Indications

colorectal cancer

Therapies

mFOLFOX-6

Bevacizumab + FOLFOX

FOLFIRI

Cetuximab + FOLFIRI

Bevacizumab + FOLFIRI

Cetuximab + FOLFOX

Pembrolizumab

Age Groups: adult

Additional content available in CKB BOOST